Literature DB >> 29335040

Does a cognitive stress test predict progression from mild cognitive impairment to dementia equally well in clinical versus population-based settings?

Joanne C Beer1, Beth E Snitz2, Chung-Chou H Chang1, David A Loewenstein3, Mary Ganguli2.   

Abstract

ABSTRACTBackground:Evidence suggests that semantic interference may be a sensitive indicator of early dementia. We examined the utility of the Semantic Interference Test (SIT), a cognitive stress memory paradigm which taps proactive and retroactive semantic interference, for predicting progression from mild cognitive impairment (MCI) to dementia in both a clinical and a population-based sample.
METHODS: Participants with MCI in the clinical (n = 184) and population-based (n = 435) samples were followed for up to four years. We employed receiver operating characteristic (ROC) methods to establish optimal thresholds for four different SIT indices. Threshold performance was compared in the two samples using logistic and Cox proportional hazard regression models.
RESULTS: Within four years, 42 (22.8%) MCI individuals in the clinical sample and 45 (10.3%) individuals in the population-based sample progressed to dementia. Overall classification accuracy of SIT thresholds ranged from 61.4% to 84.8%. Different subtests of the SIT had slightly different performance characteristics in the two samples. However, regression models showed that thresholds established in the clinical sample performed similarly in the population sample before and after adjusting for demographics and other baseline neuropsychological test scores.
CONCLUSIONS: Despite differences in demographic composition and progression rates, baseline SIT scores predicted progression from MCI to dementia similarly in both samples. Thresholds that best predicted progression were slightly below thresholds established for distinguishing between amnestic MCI and cognitively normal subjects in clinical practice. This confirms the utility of the SIT in both clinical and population-based samples and establishes thresholds most predictive of progression of individuals with MCI.

Entities:  

Keywords:  Alzheimer's disease; dementia; memory; mild cognitive impairment; neuropsychological tests

Mesh:

Year:  2018        PMID: 29335040      PMCID: PMC6047940          DOI: 10.1017/S1041610217002666

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN: 1041-6102            Impact factor:   3.878


  13 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Vulnerability to proactive semantic interference and progression to dementia among older adults with mild cognitive impairment.

Authors:  David A Loewenstein; Amarilis Acevedo; Joscelyn Agron; Ranjan Duara
Journal:  Dement Geriatr Cogn Disord       Date:  2007-10-02       Impact factor: 2.959

3.  A Novel Cognitive Stress Test for the Detection of Preclinical Alzheimer Disease: Discriminative Properties and Relation to Amyloid Load.

Authors:  David A Loewenstein; Rosie E Curiel; Maria T Greig; Russell M Bauer; Marian Rosado; Dawn Bowers; Meredith Wicklund; Elizabeth Crocco; Michael Pontecorvo; Abhinay D Joshi; Rosemarie Rodriguez; Warren W Barker; Jacqueline Hidalgo; Ranjan Duara
Journal:  Am J Geriatr Psychiatry       Date:  2016-04-04       Impact factor: 4.105

4.  Age and education correction of Mini-Mental State Examination for English and Spanish-speaking elderly.

Authors:  D Mungas; S C Marshall; M Weldon; M Haan; B R Reed
Journal:  Neurology       Date:  1996-03       Impact factor: 9.910

5.  Cognitive test performance predicts change in functional status at the population level: the MYHAT Project.

Authors:  Mary Ganguli; Joni Vander Bilt; Ching-Wen Lee; Beth E Snitz; Chung-Chou H Chang; David A Loewenstein; Judith A Saxton
Journal:  J Int Neuropsychol Soc       Date:  2010-07-08       Impact factor: 2.892

6.  Semantic interference deficits and the detection of mild Alzheimer's disease and mild cognitive impairment without dementia.

Authors:  David A Loewenstein; Amarilis Acevedo; Cheryl Luis; Thomas Crum; Warren W Barker; Ranjan Duara
Journal:  J Int Neuropsychol Soc       Date:  2004-01       Impact factor: 2.892

7.  How much do depressive symptoms affect cognition at the population level? The Monongahela-Youghiogheny Healthy Aging Team (MYHAT) study.

Authors:  Mary Ganguli; Beth Snitz; Joni Vander Bilt; Chung-Chou H Chang
Journal:  Int J Geriatr Psychiatry       Date:  2009-11       Impact factor: 3.485

8.  Proactive Semantic Interference is Associated with Total and Regional Abnormal Amyloid Load in Non-Demented Community-Dwelling Elders: A Preliminary Study.

Authors:  David A Loewenstein; Maria T Greig; Rosie Curiel; Rosemarie Rodriguez; Meredith Wicklund; Warren W Barker; Jacqueline Hidalgo; Marian Rosado; Ranjan Duara
Journal:  Am J Geriatr Psychiatry       Date:  2015-07-26       Impact factor: 4.105

9.  A novel approach to assessing memory at the population level: vulnerability to semantic interference.

Authors:  Beth E Snitz; David A Loewenstein; Chung-Chou H Chang; Ching-Wen Lee; Joni Vander Bilt; Judith Saxton; Mary Ganguli
Journal:  Int Psychogeriatr       Date:  2010-01-28       Impact factor: 3.878

10.  pROC: an open-source package for R and S+ to analyze and compare ROC curves.

Authors:  Xavier Robin; Natacha Turck; Alexandre Hainard; Natalia Tiberti; Frédérique Lisacek; Jean-Charles Sanchez; Markus Müller
Journal:  BMC Bioinformatics       Date:  2011-03-17       Impact factor: 3.307

View more
  1 in total

1.  Alzheimer's disease pathology in a community-based sample of older adults without dementia: The MYHAT neuroimaging study.

Authors:  Kevin J Sullivan; Anran Liu; Chung-Chou H Chang; Ann D Cohen; Brian J Lopresti; Davneet S Minhas; Charles M Laymon; William E Klunk; Howard Aizenstein; Neelesh K Nadkarni; David Loewenstein; M Ilyas Kamboh; Mary Ganguli; Beth E Snitz
Journal:  Brain Imaging Behav       Date:  2020-08-03       Impact factor: 3.224

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.